- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03956355
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
September 16, 2022 updated by: Dermavant Sciences GmbH
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults.
Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a 12-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 12 weeks.
At the end of the 12-week study treatment, qualified subjects completing the study will have the option to enter a separate open-label, long-term safety and efficacy study for an additional 40 weeks of treatment with tapinarof cream, 1%.
Subjects who do not enroll in the open-label long-term study will complete a follow-up visit approximately 4 weeks after end of treatment in this study (at Week 16).
Study Type
Interventional
Enrollment (Actual)
510
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Newfoundland and Labrador
-
Saint Johns, Newfoundland and Labrador, Canada, A1C 2H5
- Dermavant Investigative Site
-
-
Ontario
-
Ajax, Ontario, Canada, L1S 7K8
- Dermavant Investigative Site
-
Coburg, Ontario, Canada, K9A 0Z4
- Dermavant Investigative Site
-
North Bay, Ontario, Canada, P1B 3Z7
- Dermavant Investigative Site
-
Richmond Hill, Ontario, Canada, L4C 9M7
- Dermavant Investigative Site
-
Toronto, Ontario, Canada, M3H 5Y8
- Dermavant Investigative Site
-
Waterloo, Ontario, Canada, N2J 1C4
- Dermavant Investigative Site
-
Windsor, Ontario, Canada, N8W 5L7
- Dermavant Investigative Site
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 2V1
- Dermavant Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Dermavant Investigative Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Dermavant Investigative Site
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- Dermavant Investigative Site
-
Rogers, Arkansas, United States, 72758
- Dermavant Investigative Site
-
-
California
-
Anaheim Hills, California, United States, 92807
- Dermavant Investigative Site
-
Fresno, California, United States, 93720
- Dermavant Investigative Site
-
Los Angeles, California, United States, 90033
- Dermavant Investigative Site
-
Northridge, California, United States, 91324
- Dermavant Investigative Site
-
San Diego, California, United States, 92123
- Dermavant Investigative Site
-
Santa Ana, California, United States, 92701
- Dermavant Investigative Site
-
-
Connecticut
-
Cromwell, Connecticut, United States, 06416
- Dermavant Investigative Site
-
-
Florida
-
Boca Raton, Florida, United States, 33431
- Dermavant Investigative Site
-
Brandon, Florida, United States, 33511
- Dermavant Investigative Site
-
Hialeah, Florida, United States, 33016
- Dermavant Investigative Site
-
Miramar, Florida, United States, 33027
- Dermavant Investigative Site
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Dermavant Investigative Site
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Dermavant Investigative Site
-
Indianapolis, Indiana, United States, 46250
- Dermavant Investigative Site
-
New Albany, Indiana, United States, 47150
- Dermavant Investigative Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Dermavant Investigative Site
-
Owensboro, Kentucky, United States, 42301
- Dermavant Investigative Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Dermavant Investigative Site
-
New Orleans, Louisiana, United States, 70115
- Dermavant Investigative Site
-
New Orleans, Louisiana, United States, 70112
- Dermavant Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dermavant Investigative Site
-
-
Michigan
-
Clarkston, Michigan, United States, 48346
- Dermavant Investigative Site
-
Warren, Michigan, United States, 48088
- Dermavant Investigative Site
-
-
Missouri
-
Saint Joseph, Missouri, United States, 64506
- Dermavant Investigative Site
-
-
New Jersey
-
Verona, New Jersey, United States, 07044
- Dermavant Investigative Site
-
-
New York
-
Kew Gardens, New York, United States, 11374
- Dermavant Investigative Site
-
New York, New York, United States, 10029
- Dermavant Investigative Site
-
Rochester, New York, United States, 14623
- Dermavant Investigative Site
-
-
North Carolina
-
Cary, North Carolina, United States, 27518
- Dermavant Investigative Site
-
High Point, North Carolina, United States, 27262
- Dermavant Investigative Site
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73071
- Dermavant Investigative Site
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Dermavant Investigative Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Dermavant Investigative Site
-
-
Rhode Island
-
Johnston, Rhode Island, United States, 02919
- Dermavant Investigative Site
-
-
Texas
-
Arlington, Texas, United States, 76011
- Dermavant Investigative Site
-
College Station, Texas, United States, 77802
- Dermavant Investigative Site
-
Dripping Springs, Texas, United States, 78620
- Dermavant Investigative Site
-
Houston, Texas, United States, 77004
- Dermavant Investigative Site
-
San Antonio, Texas, United States, 78213
- Dermavant Investigative Site
-
-
Utah
-
West Jordan, Utah, United States, 84088
- Dermavant Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female subjects ages 18 to 75 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 6 months prior to the study.
- BSA involvement ≥ 3% and ≤ 20%
- A PGA score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline
- Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study, including screening, during the treatment period, and for at least 4 weeks after the last exposure to study treatment
- Capable of giving written informed consent
Exclusion Criteria:
- Psoriasis other than plaque variant
- Any sign of infection of any of the psoriatic lesions
- Concurrent conditions or history of other diseases:
- Immunocompromised at Screening
- Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the Baseline visit
- Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox) skin infection within 1 week prior to the Baseline visit
- Significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5x the upper limit of normal (ULN)
- Total bilirubin > 1.5 x ULN; total bilirubin > ULN and ≤ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%
- Corrected QT interval > 475
- Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result, or a positive anti-hepatitis B core antigen (anti-HBc) result
- Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis
- Use of any prohibited medication within the indicated period before the first dose of study drug
- Within a minimum of 5 half-lives for biologic agents:
- Within 4 weeks for systemic immunosuppressive or immunomodulating agents, fumaric acid derivatives, vitamin D3 and analogs, retinoids, psoralens, corticosteroids, adrenocorticotropic hormone analogs, and tazarotene
- 2 weeks for immunizations with a live viral component; drugs known to possibly worsen psoriasis, unless on a stable dose for > 12 weeks
- With the exception of non-medicated emollients, 2 weeks for topical treatments including corticosteroids, immunomodulators, anthralin (dithranol), vitamin D derivatives or coal tar.
- Pregnant females or lactating females
- History of sensitivity to the study drugs, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates the subject's participation in the study
- The subject has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug
- Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
- Subjects with active infection that required oral, intramuscular, or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days of Baseline/Day 1
- Previous known participation in a clinical study with tapinarof
- Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with interpretation of the results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tapinarof (DMVT-505)
Tapinarof (DMVT-505) Cream Group
|
Tapinarof cream, 1%, applied once daily
Other Names:
|
Placebo Comparator: Vehicle Cream
Vehicle Cream Group
|
Vehicle cream applied once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation
Time Frame: Baseline to Week 12
|
The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint.
A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation.
The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4).
Higher PGA scores represent more severe disease.
Analyses were done using multiple imputation.
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Subjects With ≥ 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.
Time Frame: Baseline to Week 12
|
The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease).
The body is divided into 4 areas for scoring (head, arms, trunk, and legs).
Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale.
The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe.
Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-<10%), 2 = (10-<30%), 3 = (30-<50%), 4 = (50 -<70%), 5 = (70-<90%), 6 = (90-100%).
The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score.
Higher scores indicate more severe disease.
PASI is a static assessment made without reference to previous scores.
Analyses were done using multiple imputation.
|
Baseline to Week 12
|
Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.
Time Frame: Baseline to Week 12
|
The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint.
A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation.
The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4).
Higher PGA scores represent more severe disease.
Analyses were done using multiple imputation.
|
Baseline to Week 12
|
Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12
Time Frame: Baseline to Week 12
|
Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA.
Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)].
Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
|
Baseline to Week 12
|
Percent of Subjects With ≥90% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.
Time Frame: Baseline to Week 12
|
The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease).
The body is divided into 4 areas for scoring (head, arms, trunk, and legs).
Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale.
The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe.
Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-<10%), 2 = (10-<30%), 3 = (30-<50%), 4 = (50 -<70%), 5 = (70-<90%), 6 = (90-100%).
The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score.
Higher scores indicate more severe disease.
PASI is a static assessment made without reference to previous scores.
Analyses were done using multiple imputation.
|
Baseline to Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Victoria Butners, Dermavant Sciences GmbH
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 21, 2019
Primary Completion (Actual)
May 26, 2020
Study Completion (Actual)
May 26, 2020
Study Registration Dates
First Submitted
May 16, 2019
First Submitted That Met QC Criteria
May 17, 2019
First Posted (Actual)
May 20, 2019
Study Record Updates
Last Update Posted (Actual)
October 13, 2022
Last Update Submitted That Met QC Criteria
September 16, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DMVT-505-3001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plaque Psoriasis
-
UCB Biopharma SRLRecruitingModerate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque PsoriasisUnited States, Canada, Puerto Rico
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
-
Biocon Biologics Inc.MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. LtdCompletedHulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and ImmunogenicityModerate Chronic Plaque Psoriasis | Severe Chronic Plaque PsoriasisBulgaria, Czechia, Estonia, Poland
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisChina
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
Clinical Trials on Tapinarof
-
Psoriasis Treatment Center of Central New JerseyCompleted
-
Dermavant Sciences, Inc.RecruitingPlaque PsoriasisUnited States, Canada
-
Dermavant Sciences, Inc.Completed
-
Dermavant Sciences, Inc.Completed
-
Dermavant Sciences, Inc.CompletedAtopic DermatitisUnited States, Canada
-
Dermavant Sciences GmbHIQVIA BiotechCompletedPlaque PsoriasisUnited States, Canada
-
Dermavant Sciences GmbHIQVIA BiotechCompletedPlaque PsoriasisUnited States, Canada
-
Dermavant Sciences, Inc.CompletedAtopic DermatitisUnited States, Canada
-
Dermavant Sciences GmbHCompletedAtopic DermatitisUnited States, Canada
-
Dermavant Sciences GmbHCompletedAtopic DermatitisUnited States, Canada